Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition.

Journal of proteome research - 2 Dec 2016

Sharma Ritin, Fedorenko Inna, Spence Paige T, Sondak Vernon K, Smalley Keiran S M, Koomen John M

Abstract excerpt

Patients with BRAF V600E mutant melanoma are typically treated with targeted BRAF kinase inhibitors, such as vemurafenib and dabrafenib. Although these drugs are initially effective, they are not curative. Most of the focus to date has been upon genetic mechanisms of acquired resistance; therefore, we must better understand the global signaling adaptations that mediate escape from BRAF inhibition. In the current...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzymes

Share to Gene Expression Regulation, Neoplastic

Share to Melanoma

Share to Phosphotransferases

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 27934295
DOI: 10.1021/acs.jproteome.6b00613
PMCID: PMC5642956

Genes

BRAF
PTEN
SLK
TAOK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition.PMID 27934295Read ↗

MAPK Pathway Inhibition Reshapes Kinase Chemical Probe Reactivity Reflecting Cellular Activation StatesSemantic proximity Read ↗

Multi-omics analysis delineates resistance mechanisms associated with BRAF inhibition in melanoma cells.Semantic proximity Read ↗

Signaling and transcriptional dynamics underlying early adaptation to oncogenic BRAF inhibitionSemantic proximity Read ↗

Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities.Semantic proximity Read ↗

Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanomaSemantic proximity Read ↗

Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanomaSemantic proximity Read ↗

Function and evolution of B-Raf loop dynamics relevant to cancer recurrence under drug inhibition.Semantic proximity Read ↗

Towards a unified model of RAF inhibitor resistance.Semantic proximity Read ↗

Tyrosine phosphoproteome profiling identifies cell-intrinsic signals limiting the efficacy of tyrosine kinase inhibitor therapiesSemantic proximity Read ↗

A system-wide approach to monitor responses to synergistic BRAF and EGFR inhibition in colorectal cancer cellsSemantic proximity Read ↗

Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells.Semantic proximity Read ↗

Quantitative Tyr Phosphoproteomic Analyses Identify Cholesterol as a Master Regulator of the Tumor Adaptive Resistance to MAPK InhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.